This compound is a nitrobenzene derivative with a complex polycyclic structure, used primarily as an intermediate in pharmaceutical research and manufacturing. It features multiple amine groups, an ether linkage, and aromatic rings, contributing to its lipophilic and polar characteristics.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 1421372-67-9
Mutated EGFR-IN-1
EGFR inhibitor research compound
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine
pharmaceutical intermediate for osimertinib
2-Bromo-4-fluorotoluene
Pharmaceutical intermediate for synthesis
(1S,2S,3S,5S)-5-(2-Amino-6-(benzyloxy)-9H-purin-9-yl)-3-(benzyloxy)-2-(benzyloxymethyl)cyclopentanol
Pharmaceutical intermediate
(1S,2S,3S,5S)-3-(benzyloxy)-5-(6-(benzyloxy)-2-(((4-methoxyphenyl)diphenylmethyl)amino)-9H-purin-9-yl)-2-((benzyloxy)methyl)cyclopentanol
entecavir intermediate
(3R,4S)-3-FLUOROOXAN-4-OL
Pharmaceutical intermediate for drug synthesis
Mobocertinib
active pharmaceutical ingredient
Mobocertinib succinate
active pharmaceutical ingredient
4-N-[2-(dimethylamino)ethyl]-2-methoxy-4-N-methyl-1-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]-5-nitrobenzene-1,4-diamine
PKEPAQKEINNCAB-UHFFFAOYSA-N
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=CC(=C(C=C4OC)N(C)CCN(C)C)[N+](=O)[O-]